Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda with chemoradiotherapy in muscle invasive bladder cancer
NCT02662062Phase 2Completed
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Jul 2017
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in Muscle Invasive Bladder Cancer (MIBC), sponsored by ANZUP Cancer Trials Group. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT02662062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662062.